Ticker
ACRX

Price
0.31
Stock movement down
-0.01 (-4.26%)
Company name
AcelRx Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Markedsverdi
45.61M
Ent verdi
134.03M
Pris/omsetning
51.42
Pris/bok
-
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-72.07%
3 års avkastning
-47.96%
5 års avkastning
-36.28%
10 års avkastning
-20.28%
Sist oppdatert: 2022-08-25

UTBYTTE

ACRX betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning51.42
Pris til bok-
EV i forhold til salg151.10

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall147.12M
EPS (TTM)-0.27
FCF per aksje (TTM)-0.24

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)887.00K
Bruttofortjeneste (TTM)-2.61M
Driftsinntekter (TTM)-35.82M
Netto inntekt (TTM)-34.82M
EPS (TTM)-0.27
EPS (1 år fremover)-0.14

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-294.25%
Driftsmargin (TTM)-4038.11%
Fortjenestemargin (TTM)-3925.25%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter21.82M
Netto fordringer184.00K
Samlede omløpsmidler42.81M
Goodwill0.00
Immaterielle eiendeler8.82M
Eiendom, anlegg og utstyr0.00
Sum eiendeler71.97M
Leverandørgjeld2.71M
Kortsiktig/nåværende langsiktig gjeld16.62M
Sum kortsiktig gjeld17.03M
Sum gjeld110.24M
Aksjonærenes egenkapital-38.27M
Netto varige driftsmidler-35.89M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-29.23M
Kapitalutgifter (TTM)1.89M
Fri kontantstrøm (TTM)-31.12M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-
Avkastning på eiendeler-48.38%
Avkastning på investert kapital123.13%
Kontantavkastning på investert kapital110.06%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning0.31
Daglig høy0.33
Daglig lav0.30
Daglig volum1.29M
Tidenes høyeste13.12
1 år analytikerestimat4.25
Beta0.60
EPS (TTM)-0.27
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon14 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACRXS&P500
Nåværende prisfall fra toppnotering-97.64%-13.41%
Høyeste prisfall-98.64%-56.47%
Dato for høyeste fall12 May 20229 Mar 2009
Gj.snittlig fall fra topp-62.72%-11.38%
Gj.snittlig tid til ny topp111 days12 days
Maks tid til ny topp2290 days1805 days
SELSKAPSOPPLYSNINGER
ACRX (AcelRx Pharmaceuticals Inc) company logo
Markedsverdi
45.61M
Markedsverdi kategori
Small-cap
Beskrivelse
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Ansatte
43
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Vincent J. Angotti
Land
USA
By
Redwood City
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised set...
6. september 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
25. august 2022
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
11. august 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
11. august 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
11. august 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setti...
10. august 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022. ...
28. juli 2022
Over the last month the AcelRx Pharmaceuticals, Inc. ( NASDAQ:ACRX ) has been much stronger than before, rebounding by...
8. juli 2022
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised set...
20. mai 2022
The FDA has recently modified the AcelRx Pharmaceuticals Inc's (NASDAQ: ACRX) Dsuvia Risk Evaluation and Mitigation Strategies (REMS) requirements for healthcare setting audits. The Dsuvia REMS progra...
19. mai 2022
Neste side